Akros U.S. AI Software TOP4 Plus Index
Concentrated exposure to U.S. AI software leaders across platforms and verticals.
Sentiment Summary
Recent Events
ServiceNow Q2 2026 earnings release is scheduled for 2026-07-22. Medium importance is estimated as historical earnings volatility for this stock is approximately 5-7% and the event is scheduled.
Oracle is expected to report its Q4 FY2026 earnings results around June 10, 2026, based on past reporting schedules. Medium importance is estimated as earnings releases typically result in a price impact of 5% or more, expected.
Salesforce is scheduled to release its first quarter fiscal 2027 financial results after the market closes on May 27, 2026. High impact is estimated based on historical earnings volatility, scheduled.
Snowflake is scheduled to release its financial results for the first quarter of fiscal year 2027, which ended April 30, 2026, after the close of U.S. markets on May 27, 2026. This is a future event, so the market impact is not yet known, but earnings releases are typically high-impact events, scheduled.
Bank of America analyst Tal Liani reinstated coverage on Salesforce with an 'Underperform' rating and a $160 price target on May 18, 2026, forecasted.
CEO Marc Benioff stated on May 18, 2026, that the company plans to spend nearly $300 million on Anthropic AI tokens in 2026 for AI-assisted software development.
Bank of America analysts forecast a 'Buy' rating and a $130 price target on 2026-05-18, citing ServiceNow's role in AI; the stock rallied over 8% and the price target is estimated.
Analysts from Piper Sandler and Goldman Sachs lowered their 12-month price targets for Figma on May 15, 2026, citing valuation concerns and margin pressures, forecasted.
Figma announced Q1 2026 financial results on May 14, 2026, beating analyst expectations with revenue of $333.4 million and non-GAAP EPS of $0.10, leading to a significant stock price increase.
Announced an expanded strategic collaboration with Bristol Myers Squibb to use AI and real-world data to optimize clinical trial designs for five initial programs in oncology and neuroscience.